Case report of combination therapy with Azacytidine, Enasidenib and Venetoclax in primary refractory AML

Optimal treatment of acute myeloid leukemia (AML) arising in elderly patients remains a challenge. FDA approval of Ivosidenib and Enasidenib, small molecule inhibitors of isocitrate dehydrogenase enzymes (IDH1 and 2) have opened new avenues of treatment. We present a 60-year-old woman with refractor...

Descripción completa

Detalles Bibliográficos
Autores principales: Jasra, Sakshi, Kazemi, Mohammed, Shah, Nishi, Chen, Jiahao, Fehn, Karen, Wang, Yanhua, Mantzaris, Ioannis, Kornblum, Noah, Sica, Alejandro, Bachier, LizaMarie, Goldfinger, Mendel, Gritsman, Kira, Braunschweig, Ira, Steidl, Ulrich, Shastri, Aditi, Verma, Amit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7784272/
https://www.ncbi.nlm.nih.gov/pubmed/33397455
http://dx.doi.org/10.1186/s40164-020-00186-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7784272/
https://www.ncbi.nlm.nih.gov/pubmed/33397455
http://dx.doi.org/10.1186/s40164-020-00186-y

Ejemplares similares